How to Use Gemcitabine Hydrochloride for Injection?

Update Date: 2024-05-21 Source: Network

Gemcitabine hydrochloride for injection should be used under the guidance of experienced oncologists.

The recommended dose for the treatment of non-small cell lung cancer is 1000mg/m2, administered intravenously over 30 minutes. For the treatment of breast cancer, the recommended dose is 1250mg/m2, also administered intravenously over 30 minutes. It is recommended to refer to existing clinical trial data and adjust the dosage based on individual clinical situations.

Methods of Administration for Gemcitabine Hydrochloride for Injection:

1. Monotherapy for non-small cell lung cancer: The recommended dose of gemcitabine is 1000mg/m2, administered intravenously over 30 minutes. Administration is once weekly for 3 weeks followed by a 1-week rest period, repeating this 4-week treatment cycle. Depending on the patient's tolerance to gemcitabine, a dose reduction may be considered within each treatment cycle or across treatment cycles.

Combination therapy: When gemcitabine is combined with cisplatin for a 3-week treatment cycle, the recommended dose of gemcitabine is 1250mg/m2, administered intravenously over 30 minutes. Administration occurs on day 1, day 8, and day 15 of each 28-day treatment cycle. Depending on the patient's tolerance to gemcitabine, a dose reduction may be considered within each treatment cycle or across treatment cycles.

2. Pancreatic cancer: The recommended dose of gemcitabine is 1000mg/m2, administered intravenously over 30 minutes. Administration is once weekly for 7 consecutive weeks, followed by a 1-week rest period. This is then followed by a 4-week treatment schedule where gemcitabine is administered once weekly for 3 weeks, followed by a 1-week rest period. Depending on the patient's tolerance to gemcitabine, a dose reduction may be considered within each treatment cycle or across treatment cycles.

3. Breast cancer: It is recommended to use gemcitabine in combination with paclitaxel. Paclitaxel (175mg/m2) is administered intravenously over approximately 3 hours on day 1 of each 21-day treatment cycle, followed by gemcitabine (1250mg/m2) on day 1 and day 8, administered intravenously over 30 minutes. Depending on the patient's tolerance to gemcitabine, a dose reduction may be considered within each treatment cycle or across treatment cycles. Before receiving the combination chemotherapy of gemcitabine and paclitaxel, the patient's absolute granulocyte count should be at least 1,500 (×106/L).

Indications for Gemcitabine Hydrochloride for Injection:

This product can be used to treat the following diseases: locally advanced or metastatic non-small cell lung cancer; locally advanced or metastatic pancreatic cancer; and, in combination with paclitaxel, for the treatment of recurrent, unresectable, locally recurrent, or metastatic breast cancer after adjuvant/neoadjuvant chemotherapy. Unless contraindicated clinically, anthracycline antibiotics should have been used in previous chemotherapy.